Overview of scleroderma manifestations, organ involvement, brief classifications (limited, diffuse, sine scleroderma). Overview of current treatment options, need for additional therapies. Overview of plan for multi-disciplinary scleroderma center at the University of Chicago. Potential future therapies in the literature at large. Planned trials/future treatment options at the University of Chicago. For more info about scleroderma and the foundation, head to www.stopscleroderma.org This talk was presented at the Scleroderma Patient Education Conference on May 4, 2024, hosted by the Scleroderma Foundation of Greater Chicago.

1. SCLERODERMA: TREATMENT
OPTIONS AND A LOOK TO
THE FUTURE
Michael Macklin MD, PharmD
University of Chicago

2. OBJECTIVES
• Classification and manifestations of scleroderma
• Overview of treatment options for scleroderma
• Potential treatments on the horizon at large and at the University of Chicago
• Multi disciplinary care in scleroderma

3. ETIOLOGY
• Scleroderma is an incompletely understood disease
• There is clearly an autoimmune basis with vascular dysfunction, and activation of
fibroblasts leading to fibrosis

4. Benfaremo D, Svegliati S, Paolini C, Agarbati S, Moroncini G. Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines. 2022; 10(1):163. https://doi.org/10.3390/biomedicines10010163

5. CLASSIFICATION
• Limited: Skin involvement that does not go past elbows or knees for limbs, no trunk
involvement, face/neck can be involved
• Diffuse: Skin involvement that does go past elbows or knees for limbs, trunk
involvement, face/neck can be involved
• Sine scleroderma: No skin involvement, still has Raynaud's, antibodies, internal
organ involvement

6. CLASSIFICATION
• Limited and diffuse tend to have different antibody profiles (SCL-70 for diffuse,
centromere for limited)
• Diffuse tends to have an aggressive course initially then becomes less active
overtime while limited is more slowly but consistently progressive
• Diffuse has more direct lung damage (interstitial lung disease) while limited has
more lung blood vessel involvement (pulmonary artery hypertension)
• Diffuse in general is more “fibrotic”, limited in general is more “vascular”

7. SKIN MANIFESTATIONS
• Scleroderma/sclerodactyly with skin thickening
• Telangiectasia
• Calcinosis
• Salt and pepper appearance

8. Mammino , J. (n.d.). Systemic sclerosis . American Osteopathic College of Dermatology . https://www.aocd.org/page/SystemicSclerosis

9. McMichael , J. (2018, November 7). Prayer sign. Twitter . https://twitter.com/globaldermie

10. July 22, 2021,N Engl J Med 2021; 385:357DOI: 10.1056/NEJMicm2103390

11. Barrett, C. (2017, August 16). Clinical Signs of Systemic Sclerosis. Stanford Medicine 25. https://stanfordmedicine25.stanford.edu/blog/archive/2017/scleroderma.html

12. YAMAMOTO T. MULTIPLE CALCINOSIS CUTIS AS A RESULT OF KÖBNER PHENOMENON IN A PATIENT WITH SYSTEMIC SCLEROSIS. OUR DERMATOL ONLINE. 2020;11(E):E176.1-E176.2

13. GASTROINTESTINAL
MANIFESTATIONS
• Gastric antral vascular ectasia (GAVE)
• Esophageal dysmotility with trouble swallowing, reflux (GERD)
• Intestinal dysmotility
• Gastroparesis (Delayed gastric emptying)
• Malnutrition

14. (2014, SEPTEMBER 20). GAVE (GASTRIC ANTRAL VASCULAR ECTASIA). UPDATE IN GASTROENTEROLOGY. HTTPS://UPTODATEGASTRO.WORDPRESS.COM/2014/09/20/GAVE-GASTRIC-ANTRAL-
VASCULAR-ECTASIA/

15. LUNG INVOLVEMENT
• Interstitial lung disease (Inflammation and fibrosis within the lung tissue)
• Pulmonary artery hypertension (high blood pressure in the pulmonary artery)

16. Weerakkody, Y. (2023, May 15). Scleroderma (pulmonary manifestations): Radiology reference article.
Radiopaedia. https://radiopaedia.org/articles/scleroderma-pulmonary-manifestations-1
Di Muzio B, Normal chest CT. Case study, Radiopaedia.org (Accessed on 09 Feb
2024) https://doi.org/10.53347/rID-41162

17. Phillips, Q. (2022, July 18). What is pulmonary arterial hypertension (PAH)? Symptoms, Causes, Diagnosis, Treatment, and Prevention. EverydayHealth.com.
https://www.everydayhealth.com/pulmonary-arterial-hypertension

18. KIDNEY
• Scleroderma renal crisis
USMLE® Step 2 CK question of the day: Scleroderma renal crisis . Osmosis . (2023, February 22). https://www.osmosis.org/blog/2021/12/15/usmle-step-2-ck-
question-of-the-day-scleroderma-renal-crisis

19. CARDIAC
• Myocarditis (inflammation of the heart muscle)
• Pericarditis (inflammation of the sac around the heart)
• Heart failure
• Arrythmias (Abnormal heart rhythms)

20. MUSCLE
• Myositis (inflammation in muscles) in overlap
Srikantharajah, D., Lloyd, M.E. & Kiely, P.D.W. Rituximab and intravenous
immunoglobulin treatment in PM/Scl antibody-associated disease: case-based
review. Rheumatol Int 42, 359–364 (2022). https://doi.org/10.1007/s00296-021-
05075-z

21. RAYNAUD'S
• Wide variety of severity

22. October 24, 2013, N Engl J Med 2013; 369:1638, DOI: 10.1056/NEJMicm1304702

23. TREATMENT
• Much progress has been made
• Treatment generally guided by manifestations present
• Some organ involvement still has few options available

24. SKIN THICKENING
Treatment options include:
• Methotrexate (anti metabolite)
• Mycophenolate (anti metabolite)
• Rituximab? (biologic, anti B-Cell)
• Tocilizumab? (biologic, anti inflammatory signal molecule, IL-6)

25. SKIN THICKENING
• Immunoglobulin therapy? (blood product)
• Cyclophosphamide rarely (DNA disrupting agent)
• Area of significant need overall

26. TELANGIECTASIA
• Laser therapy, with dermatology

27. TELANGIECTASIA
Graham Dinsdale, Andrea Murray, Tonia Moore, Janice Ferguson, Jack Wilkinson, Helen Richards, Christopher E. M. Griffiths, Ariane L Herrick, A
comparison of intense pulsed light and laser treatment of telangiectases in patients with systemic sclerosis: a within-subject randomized trial,
Rheumatology, Volume 53, Issue 8, August 2014, Pages 1422–1430, https://doi.org/10.1093/rheumatology/keu006

28. CALCINOSIS
• Area of significant need
• Injections or compounded sodium thiosulfate cream around area
• Minocycline (oral, antibiotic/general anti-inflammatory properties)
• Tofacitinib? (Oral, targeted selective molecule, JAK inhibitor), data from myositis
• Surgical removal

29. GAVE (WATERMELON STOMACH)
• Argon plasma coagulation (laser to burn off blood vessels)
• Therapy used for other manifestations may also help

30. GAVE (WATERMELON STOMACH)
Ohira, Tetsuya et al. “Detection of active bleeding from gastric antral vascular ectasia by capsule endoscopy.” World journal of gastrointestinal endoscopy vol. 5,3 (2013): 138-40. doi:10.4253/wjge.v5.i3.138

31. DYSMOTILITY IN THE
GASTROINTESTINAL SYSTEM
• An area of great unmet need
• Proton pump inhibitors for reflux (pantoprazole, esomeprazole, etc)
• Various promotility drugs (Metoclopramide, erythromycin, pyridostigmine,
prucalopride)
• Immunoglobulin therapy? (blood product)
Nassar M, Ghernautan V, Nso N, et al. Gastrointestinal involvement in systemic sclerosis: An updated review. Medicine (Baltimore). 2022;101(45):e31780.
doi:10.1097/MD.0000000000031780
Matsuda, Kazuki M et al. “Rapid improvement of systemic sclerosis-associated intestinal pseudo-obstruction with intravenous immunoglobulin administration.” Rheumatology (Oxford,
England) vol. 62,9 (2023): 3139-3145. doi:10.1093/rheumatology/kead093

32. DYSMOTILITY IN THE
GASTROINTESTINAL SYSTEM
• Over the counter laxatives can be helpful in early stages (senna, polyethylene glycol,
etc.)
• Prolonged dysmotility can lead to diarrhea from small intestinal bowel overgrowth,
easily treatable with antibiotics
• Severe dysmotility can lead to malnutrition, need to bypass intestines, total parental
nutrition (TPN)

33. MUSCLE INVOLVEMENT
• Inflammatory myositis is also undergoing a treatment revolution
• Immunoglobulin therapy (blood product) now standard of care
• Other therapies if myositis is a predominant feature

34. SCLERODERMA RENAL CRISIS
• Prevention is important, association with high prednisone doses, especially in
patients who are RNA polymerase III positive
• Treated with high doses of blood pressure medicine, mainly angiotensin converting
enzyme inhibitors (ACEI) such as lisinopril, captopril

35. INTERSTITIAL LUNG DISEASE
(INFLAMMATION AND FIBROSIS WITHIN
THE LUNG TISSUE)
• Mycophenolate (anti metabolite) standard of care
• Azathioprine (anti metabolite), may be inferior to other options
• Rituximab (biologic, anti B-Cell)
• Tocilizumab (biologic, anti inflammatory signal molecule, IL-6)
• Tocilizumab is one of two FDA approved therapies for scleroderma, specifically for ILD (2021)
Roofeh, David et al. “Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease.” Arthritis & rheumatology (Hoboken, N.J.) vol. 73,7 (2021): 1301-
1310. doi:10.1002/art.41668
Kaufman M. FDA Approves Tocilizumab to Treat Systemic Sclerosis-Associated ILD. The Rheumatologist. Published March 25, 2021. Accessed February 17, 2024. https://www.the-
rheumatologist.org/article/fda-approves-tocilizumab-to-treat-systemic-sclerosis-associated-ild/

36. INTERSTITIAL LUNG DISEASE
(INFLAMMATION AND FIBROSIS WITHIN
THE LUNG TISSUE)
• Cyclophosphamide rarely (DNA disrupting agent)
• Combination therapy (Mycophenolate + biologic)?
• Nintedanib in cases of significant fibrosis (anti fibrotic), generally added to
immunosuppression
• Nintedanib is the only other FDA approved therapy, ILD (2019)
Putman M. FDA Approves Nintedanib for SSc-ILD, But Temper Your Expectations. The Rheumatologist. Published December 18, 2019. https://www.the-
rheumatologist.org/article/fda-approves-nintedanib-for-ssc-ild-but-temper-your-expectations/

37. PULMONARY ARTERY HYPERTENSION
(HIGH BLOOD PRESSURE IN THE
PULMONARY ARTERY)
• Managed by a pulmonary hypertension specialist (pulmonary and/or cardiology
depending on center)
• Combination therapy generally used
• Sildenafil, tadalafil (Phosphodiesterase V inhibitor) (vasodilator)
• Ambrisentan, macitentan, bosentan (endothelin receptor antagonist) (prevents
vasoconstriction)
Kuwana, Masataka et al. “Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of
the AMBITION study: post hoc analysis.” Annals of the rheumatic diseases vol. 79,5 (2020): 626-634. doi:10.1136/annrheumdis-2019-216274

38. PULMONARY ARTERY HYPERTENSION
(HIGH BLOOD PRESSURE IN THE
PULMONARY ARTERY)
• Epoprostenol, treprostinil, iloprost (prostacyclin analogues) (vasodilator)

39. HEART INVOLVMENT
• An area of great unmet need
Myocarditis (inflammation of the heart muscle)
• Immunosuppression seems to work, unknown best drug
Pericarditis (inflammation of the sac around the heart)
• Treated like pericarditis outside of scleroderma (Naproxen/ibuprofen, colchicine)

40. HEART INVOLVMENT
Heart failure/arrythmia (Abnormal heart rhythms)
• Treated like causes outside of scleroderma
• Significant heart failure from scleroderma carries a very poor prognosis

41. RAYNAUD'S
• Lifestyle modification (gloves, cold avoidance, hand warmers, etc)
• Amlodipine, nifedipine (Calcium channel blockers)
• Sildenafil, tadalafil (Phosphodiesterase V inhibitor)
• Fluoxetine? (SSRI)
• Losartan? (ARB)
• Smoking cessation!
Dziadzio, M et al. “Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.” Arthritis and rheumatism vol. 42,12 (1999):
2646-55. doi:10.1002/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T
Coleiro, B et al. “Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.” Rheumatology (Oxford, England) vol. 40,9 (2001): 1038-43. doi:10.1093/rheumatology/40.9.1038

42. RAYNAUD'S
• Botox? (controversial, may actually worsen)
• Fat transfer with plastic surgery?
• Digital sympathectomy? (surgical stripping of sympathetic nervous system)
• Bosentan (endothelin receptor antagonist) (prevents vasoconstriction)
• Epoprostenol (prostacyclin analogue) (vasodilator)
• Peripheral nerve block (temporary)
Senet, Patricia et al. “Efficacy and Safety of Botulinum Toxin in Adults with Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.” Arthritis &
rheumatology (Hoboken, N.J.) vol. 75,3 (2023): 459-467. doi:10.1002/art.42342

43. FUTURE TREATMENT
• Many potential treatment options are in development!
• Some are specific for ILD, other multiple system involvement

44. FT011
• Oral drug, Phase 2 in diffuse scleroderma
• Is a G protein-coupled receptor 68 protein sensing antagonist, inhibits pro-fibrotic and
inflammatory pathways
• Improved a variety of outcomes including lung function, skin thickening vs placebo
• GI side effects and photosensitivity seem to be the most common side effects
• Phase 3 to come
Khanna D, Spino C, Bernstein E, Goldin J, Tashkin D, roth M, SLS III Investigators O. Combination Therapy of Mycophenolate Mofetil and Pirfenidone vs. Mycophenolate Alone: Results from the
Scleroderma Lung Study III [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/combination-therapy-of-mycophenolate-mofetil-and-pirfenidone-vs-mycophenolate-
alone-results-from-the-scleroderma-lung-study-iii/. Accessed February 16, 2024

45. GUSELKUMAB
• IL-23 inhibitor (biologic)
• Used in psoriatic arthritis, psoriasis, data in Crohn’s
• Phase 2 trial in Japan
• Primary outcome is skin thickening
https://clinicaltrials.gov/study/NCT04683029

46. ANIFROLUMAB
• Type 1 interferon blocker (biologic)
• Used in Lupus, especially for skin involvement
• Phase 3 study
• Evaluating effect on lung function and skin thickening mainly
• Chicago site is planned, not yet recruiting
https://clinicaltrials.gov/study/NCT05925803

47. IXAZOMIB
• Ixazomib is an oral proteosome inhibitor
• Currently used in multiple myeloma
• Phase 2 study
• Recruiting at Mayo Clinic Arizona
• Evaluating effect on ILD and skin thickening
https://www.clinicaltrials.gov/study/NCT04837131

48. BARICITINIB
• A JAK inhibitor used in COVID-19, RA
• Phase 4 trial in China evaluating use in ILD and skin thickening compared with
cyclophosphamide
https://clinicaltrials.gov/study/NCT05300932

49. RO7303509
• RO7303509 is a biologic that targets TGF-β3 (antifibrotic)
• Phase 1A already done, recruiting for Phase 1B
• Sites include DC, Boston, Rochester MN, NYC
Han L, Jamalian S, Pan L, et alPOS1266 A PHASE IA, RANDOMIZED STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE ASCENDING
DOSES OF RO7303509, AN ANTI-TGFΒ3 MONOCLONAL ANTIBODY, IN HEALTHY VOLUNTEERS Annals of the Rheumatic Diseases 2023;82:976-977.
https://clinicaltrials.gov/study/NCT05462522

50. INEBILIZUMAB
• Anti CD19 biologic (B cell targeting)
• Phase 3 placebo-controlled study
• Evaluating skin thickening
• Taking place in Japan
• Already approved for Neuromyelitis Optica (NMO)
https://clinicaltrials.gov/study/NCT05198557

51. BELIMUMAB AND RITUXIMAB
• Belimumab is an anti B-lymphocyte stimulator (BLyS) biologic
• Currently used in Lupus
• Combination of belimumab and rituximab vs placebo
• Phase 2, recruiting in NYC
• Evaluating ILD and skin thickening
https://clinicaltrials.gov/study/NCT03844061

52. BELIMUMAB
• Primary outcome is lung function
• Phase 3 study, placebo controlled
• Northwestern is a site-recruiting per clinicaltrials.gov
https://clinicaltrials.gov/study/NCT05878717

53. IFETROBAN
• Thromboxane receptor antagonist
• Oral drug, phase 2 study, placebo controlled
• Looking specifically at both diffuse scleroderma and at patients with confirmed
pulmonary artery hypertension
• Secondary endpoints include skin thickening, lung function
• Closest sites include NYC, Philadelphia, Omaha, Boston, Baltimore
https://clinicaltrials.gov/study/NCT02682511

54. HZN-825
• HZN-825 is a lysophosphatidic acid receptor blocker, lysophosphatidic acid is
thought to be involved in fibrosis
• Phase 2 placebo-controlled study in diffuse scleroderma
• Evaluating lung function, skin thickening
• Sites include Ann Arbor, NYC, Boston, Philadelphia, Rochester MN
https://clinicaltrials.gov/study/NCT04781543

55. TULISOKIBART
• Tulisokibart is biologic targeting tumor necrosis factor (TNF)-like cytokine 1A
• Also being evaluated in IBD
• Placebo controlled phase 2 in patients with diffuse disease with ILD
• Mainly looking at lung function
• Recruiting centers include DC, Baltimore, Boston, Ann Arbor, Cleveland, Toledo,
Milwaukee, Pittsburgh, NYC
https://clinicaltrials.gov/study/NCT05270668

56. VIXARELIMAB
• Vixarelimab blocks the oncostatin M receprot, blocking signaling of oncostatin M
and interleukin 31
• Oncostatin M/IL-31 are thought to be involved in itch, inflammation and fibrosis
• Primarily evaluating lung function in ILD
• Sites include Northwestern-Glenview, Muncie IN
Sofen, Howard et al. “Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-
controlled, phase 2a study.” EClinicalMedicine vol. 57 101826. 3 Feb. 2023, doi:10.1016/j.eclinm.2023.101826
https://clinicaltrials.gov/study/NCT05785624

57. AUTOLOGOUS STEM CELL
TRANSPLANT
Chatterjee S, Majhail N. Autologous Hematopoietic Cell Transplantation: Way of the Future in Severe Systemic Sclerosis? Cleveland Clinic. Published November 30, 2018. Accessed February 17, 2024.
https://consultqd.clevelandclinic.org/autologous-hematopoietic-cell-transplantation-way-of-the-future-in-severe-systemic-sclerosis

58. AUTOLOGOUS STEM CELL
TRANSPLANT
• Has shown benefit for a variety of manifestations in scleroderma
• May be reasonable in rapidly progressive cases
• Exact patient selection evolving
• George Georges, MD at Northwestern is running a trial through heme/onc
• University of Chicago will be referring to him as appropriate
Bruera, Sebastian et al. “Stem cell transplantation for systemic sclerosis.” The Cochrane database of systematic reviews vol. 7,7 CD011819. 29 Jul. 2022, doi:10.1002/14651858.CD011819.pub2
Sullivan KM, Majhail NS, Bredeson C, et al. Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation. Biol
Blood Marrow Transplant. 2018;24(10):1961-1964. doi:10.1016/j.bbmt.2018.06.025
Sullivan KM, Shah A, Sarantopoulos S, Furst DE. Review: Hematopoietic Stem Cell Transplantation for Scleroderma: Effective Immunomodulatory Therapy for Patients With Pulmonary Involvement. Arthritis Rheumatol.
2016;68(10):2361-2371. doi:10.1002/art.39748
Panopoulos, Stylianos T et al. “Outcomes of conventionally-treated systemic sclerosis patients eligible for autologous haematopoietic stem cell transplantation.” Clinical and experimental rheumatology vol. 39 Suppl 131,4
(2021): 29-33. doi:10.55563/clinexprheumatol/dhn3mb

59. USE OF SPINAL STIMULATORS FOR
REFRACTORY RAYNAUD’S IN
CONNECTIVE TISSUE DISEASE
• Planned study in collaboration with pain management at the University of Chicago
• Planned for patient's intolerant to, or refractory to drugs such as
sildenafil/amlodipine

60. USE OF SPINAL STIMULATORS FOR
REFRACTORY RAYNAUD’S IN
CONNECTIVE TISSUE DISEASE
Wu M, Linderoth B, Foreman RD. Putative mechanisms behind effects of spinal cord stimulation on vascular diseases: a review of experimental studies. Auton
Neurosci. 2008;138(1-2):9-23. doi:10.1016/j.autneu.2007.11.001
Fiks V. Spinal cord stimulation can treat Peripheral Vascular Disease. www.apmconline.org. Accessed February 17, 2024.
https://www.apmconline.org/blog/spinal-cord-stimulation-can-treat-peripheral-vascular-disease

61. CAR T THERAPY
• University of Chicago will be a site in partnership with Cabaletta Bio Inc for
scleroderma, myositis, lupus
Klebanoff, C., Yamamoto, T. & Restifo, N. Treatment of aggressive lymphomas with anti-CD19 CAR T cells. Nat Rev Clin Oncol 11, 685–686 (2014).
https://doi.org/10.1038/nrclinonc.2014.190

62. CAR T THERAPY
• CAR T therapy may be superior to antibody targeted therapies at CD19 (B cells)
given ability of CAR T cells to move throughout body
• Skin involvement, and ILD will be main manifestations evaluated, along with cardiac
and/or renal involvement
• Significant pulmonary artery hypertension is a major exclusion criteria

64. CAR T THERAPY
• Four patients with scleroderma described
• All 4 were able to discontinue other immunosuppression
Müller, Fabian et al. “CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.” The New
England journal of medicine vol. 390,8 (2024): 687-700. doi:10.1056/NEJMoa2308917

65. CONQUEST
• University of Chicago will be a site in partnership with the Scleroderma Research
Foundation for COUNQUEST
• Multi arm study, 2 arms at UChicago, placebo controlled
• Evaluating ILD
• Background mycophenolate allowed

66. CONQUEST
• One arm will include Amlitelimab, a biologic that targets OX40L which is involved in
cytokine release and T-cell activation
• Another arm will include BI 1015550, an oral PDE4B inhibitor, which helps
downregulate a variety of proinflammatory cytokines
• BI 1015550 is similar to a drug used for psoriatic arthritis called apremilast, though
is more selective which is thought to make it have less gastrointestinal side effects

67. MULTIDISCIPLINARY SCLERODERMA
CARE
• Scleroderma is clearly a complex disorder, effecting nearly every organ in the body
• Multiple fields are needed to work together, with rheumatology often being the
primary specialty involved
• University of Chicago will be forming a multidisciplinary scleroderma program to
help improve care for scleroderma patients, and improve access in Chicago

68. MULTIDISCIPLINARY SCLERODERMA
CARE
• Rheumatology: Myself
• GI: Dejan Micic, MD
• Pain Medicine: Tariq Malik, MD; Dalia Elmofty, MD
• Renal: Marco Bonilla, MD; Zainab Obaidi, MD
• Pulmonary hypertension: Stanley Swat, MD
• Plastic Surgery: Jignesh Unadkat, MD; Summer Hanson, MD, PhD
• Dermatology: Mark Hoffman, MD
• Pulmonary: Mary Strek, MD; Cathryn Lee, MD; Ayodeji Adegunsoye, MD

69. MULTIDISCIPLINARY SCLERODERMA
CARE
• Overtime will involve dedicated time in Hyde Park on Mondays with coordination of
other fields as needed
• I will also be in Crown Point, IN and River East
• Need for other fields will be coordinated at Hyde Park

70. THANK YOU FOR YOUR ATTENTION
• Any questions?